Difficulty: Medium
Average Score: 81%
Practice
A 9-year-old boy develops acute myelogenous leukemia (AML) one year after completion of therapy for soft tissue sarcoma at his right thigh. Which of the following chemotherapeutic agents is MOST likely the cause of secondary acute myelogenous leukemia AML in this boy?
Correct answer
C
Rationale
The correct answer is C) etoposide. Etoposide is known to be associated with secondary acute myelogenous leukemia (AML) as a long-term complication of its use in cancer therapy. Etoposide can cause damage to the DNA of hematopoietic stem cells, leading to the development of AML later on.
A) Cyclophosphamide is not typically associated with secondary AML as a long-term complication.
B) Vincristine is not known to cause secondary AML.
D) Doxorubicin is not commonly associated with secondary AML.
In an educational context, it is essential for healthcare providers to be aware of the potential long-term side effects of chemotherapeutic agents. Understanding the specific risks associated with each drug can help in making informed decisions when selecting treatment options for pediatric patients. Monitoring for late effects, such as secondary malignancies, is crucial in survivorship care for pediatric oncology patients.
A) Cyclophosphamide is not typically associated with secondary AML as a long-term complication.
B) Vincristine is not known to cause secondary AML.
D) Doxorubicin is not commonly associated with secondary AML.
In an educational context, it is essential for healthcare providers to be aware of the potential long-term side effects of chemotherapeutic agents. Understanding the specific risks associated with each drug can help in making informed decisions when selecting treatment options for pediatric patients. Monitoring for late effects, such as secondary malignancies, is crucial in survivorship care for pediatric oncology patients.